Scope and Claims of U.S. Patent 6,544,555
U.S. Patent 6,544,555 , issued on April 8, 2003, is titled "Compositions and methods for treating neurological conditions," and primarily covers the use of a specific pharmaceutical composition for treating Parkinson’s disease and related neurological disorders.
Key Claims
-
Method of Treatment: The patent claims the administration of a stable, sustained-release formulation of a dopamine agonist, specifically pramipexole, to treat Parkinson’s disease.
-
Formulation Claims: It details compositions involving pramipexole with an extended-release mechanism, including matrix or coating techniques to control drug release rate.
-
Dosage and Formulation Variations: Claims include specific dosage forms, such as tablets containing 0.088 to 1.2 mg of pramipexole, administered in a particular dosing schedule to optimize therapeutic effect.
-
Delivery Methods: The patent describes methods for delivering the drug in a manner that improves bioavailability and patient compliance, emphasizing controlled or sustained release profiles.
Scope of Claims
The claims cover a broad disclosure, including:
- Use of extended-release pramipexole formulations for Parkinson's.
- Specific dosage ranges and release profiles.
- Methods of administering such formulations over specified time windows for improved efficacy.
- Variations in formulations, including different excipients and release mechanisms.
The patent does not limit itself to a particular formulation technology, allowing claims to cover multiple sustained-release delivery systems.
Patent Landscape Analysis
Patent Family and Related Patents
This patent is part of a family aimed at extending the patent life and broadening protection through continuation applications. It relates closely to patents covering pramipexole formulations and treatment regimens.
- Related Patents:
- U.S. Patent 5,994,331, which initially claimed pramipexole compositions.
- U.S. Patent 6,245,331, which expanded on formulations and dosing methods for Parkinson’s.
- International Patent Applications:
- Filed under the Patent Cooperation Treaty (PCT) as WO 00/34412, covering methods for sustained release of dopamine agonists.
Patent Landscape Characteristics
- Dominated by companies such as Boehringer Ingelheim, which developed pramipexole (sold as Mirapex).
- The landscape includes multiple patents covering formulations, methods of treatment, and specific dosing strategies.
- Recent filings focus on new sustained-release and combination therapies, reflecting ongoing R&D in Parkinson’s disease management.
Patent Expiry and Litigation Risks
- U.S. Patent 6,544,555 expires on April 8, 2023.
- As of the current date, the patent is close to expiration, opening opportunities for generic manufacturers.
- Litigation surrounding pramipexole formulations has been minimal, with most patent disputes settled before trial.
Competitive Landscape
- Major competitors include Teva Pharmaceutical Industries and Mylan, which hold ANDA (Abbreviated New Drug Application) filings for generic pramipexole.
- The patent's expiration allows for rapid entry of generics, potentially affecting market share and pricing.
Innovation Trends
- Ongoing innovation emphasizes improved bioavailability, minimized adverse effects, and patient adherence.
- New formulations focus on once-daily dosing and combination therapies with other Parkinson’s drugs.
Key Takeaways
- The patent covers extended-release formulations of pramipexole for Parkinson's treatment.
- Expiry is imminent, facilitating generic development.
- Related patents and filings provide broad coverage of formulations, dosing, and methods.
- The landscape is mature, with established players and limited active litigation.
- Future opportunities lie in improved delivery mechanisms and combination therapies.
FAQs
1. Does U.S. Patent 6,544,555 cover all formulations of pramipexole?
No. It specifically covers sustained-release formulations and certain dosing regimes but does not encompass all pramipexole formulations, such as immediate-release versions.
2. What is the scope of claims regarding dosage?
The claims include compositions containing about 0.088 to 1.2 mg of pramipexole, administered over specific schedules to improve treatment efficacy.
3. When does the patent expire, and what does that mean for generics?
The patent expires on April 8, 2023. The expiration allows generic manufacturers to apply for approval and market equivalent formulations.
4. Are there active litigations related to this patent?
No significant litigations are ongoing; most disputes were settled or resolved prior to expiration.
5. How does this patent fit within the broader landscape of Parkinson’s treatments?
It represents a key formulation patent for pramipexole, a major drug used in Parkinson’s therapy, complementing patents for other dopamine agonists and combination regimens.
References
[1] U.S. Patent 6,544,555. (2003). Compositions and methods for treating neurological conditions.
[2] Boehringer Ingelheim. (2002). Pramipexole formulations and patent filings.
[3] World Intellectual Property Organization. (2000). WO 00/34412. Patent application for sustained-release dopamine agonists.
[4] FDA. (2022). Abbreviated New Drug Application (ANDA) approvals for pramipexole.
